Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia

Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects

(2015) J. Wellbrock et al.   CLINICAL CANCER RESEARCH

GLI2 inhibition abrogates human leukemia stem cell dormancy

(2015) Anil Sadarangani et al.   Journal of Translational Medicine

Chronic myeloid leukaemia

(2015) Jane F Apperley   LANCET

Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened

(2015) Annelies Gonnissen et al.   Oncotarget

PTCH1expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase

(2014) Juan M. Alonso-Dominguez et al.   AMERICAN JOURNAL OF HEMATOLOGY

EBV-positive peripheral T-cell lymphoma with extensive hemophagocytosis

(2014) M. V. Shah et al.   BLOOD

Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer

(2014) Jillian Brechbiel et al.   CANCER TREATMENT REVIEWS

A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors

(2014) J. Rodon et al.   CLINICAL CANCER RESEARCH

A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia

(2014) J. E. Lancet et al.   HAEMATOLOGICA

Combination of Ponatinib with Hedgehog Antagonist Vismodegib for Therapy-Resistant BCR-ABL1-Positive Leukemia

(2013) S. Katagiri et al.   CLINICAL CANCER RESEARCH

Targeting hedgehog in hematologic malignancy

(2012) D. A. Irvine et al.   BLOOD

Effects of the Hedgehog Inhibitor GDC-0449, Alone or in Combination with Dasatinib, on BCR-ABL-Positive Leukemia Cells

(2012) Seiichi Okabe et al.   STEM CELLS AND DEVELOPMENT

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival

(2011) A. Hamilton et al.   BLOOD

Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment

(2011) S. Chu et al.   BLOOD

Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease

(2011) J.-C. Chomel et al.   BLOOD

Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib

(2011) A. Kumari et al.   BLOOD

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

(2011) J. E. Cortes et al.   BLOOD

Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia

(2011) Leisl M. Packer et al.   CANCER CELL

Activation of the hedgehog pathway in chronic myelogeneous leukemia patients

(2011) Bing Long et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

ATM and p53 Regulate FOXM1 Expression via E2F in Breast Cancer Epirubicin Treatment and Resistance

(2011) J. Millour et al.   MOLECULAR CANCER THERAPEUTICS

Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate

(2010) Bin Zhang et al.   CANCER CELL

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

(2010) Amie S. Corbin et al.   JOURNAL OF CLINICAL INVESTIGATION

Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant

(2010) Wei-Sheng Huang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

(2010) D M Ross et al.   LEUKEMIA

Hedgehog signaling maintains chemoresistance in myeloid leukemic cells

(2010) K C S Queiroz et al.   ONCOGENE

Self-Renewal of Acute Lymphocytic Leukemia Cells Is Limited by the Hedgehog Pathway Inhibitors Cyclopamine and IPI-926

(2010) Tara L. Lin et al.   PLoS One

Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist

(2010) Shifeng Pan et al.   ACS Medicinal Chemistry Letters

Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia

(2009) Chen Zhao et al.   NATURE

Expansion of Bcr-Abl-Positive Leukemic Stem Cells Is Dependent on Hedgehog Pathway Activation

(2008) Christine Dierks et al.   CANCER CELL

Hedgehog Signaling in Development and Cancer

(2008) Jin Jiang et al.   DEVELOPMENTAL CELL

Intrinsic and extrinsic control of haematopoietic stem-cell self-renewal

(2008) Leonard I. Zon   NATURE

Analyzing real-time PCR data by the comparative CT method

(2008) Thomas D Schmittgen et al.   Nature Protocols

Signaling pathways governing stem-cell fate

(2007) U. Blank et al.   BLOOD